Cizzle Bio’s Dr. Steven Rosen Joins Cancer Research Leaders at GCRIS

News
Written By Cizzle Bio, Inc.
Panelists seated onstage beneath an AVBCC banner at the 2026 Global Cancer Research & Innovation Symposium in New York City.

Dr. Steven T. Rosen, Scientific Advisor to Cizzle Bio, joined leading cancer researchers at the Global Cancer Research & Innovation Symposium (GCRIS) on October 6, 2026, in New York City. Hosted by the Association for Value-Based Cancer Care (AVBCC), the symposium brought together leaders in science, medicine, biotechnology and investment to explore how cancer research can move closer to patient care.

Rosen participated in the panel Swim Across America Pioneers: “What We are Doing in Our Labs Today?”, alongside researchers from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory Cancer Center. The discussion spotlighted research underway in leading cancer laboratories.

Scientific Expertise Behind Cizzle Bio’s Lung Cancer Biomarker Test

His participation underscores the scientific and clinical expertise guiding Cizzle Bio’s work in early lung cancer detection. The company’s CIZ1B Biomarker Blood Test for Lung Cancer is designed to complement standard-of-care diagnostics with additional biomarker information to support clinical decision-making.

Read the full press release for Dr. Rosen’s perspective, commentary from Cizzle Bio CEO Bill Behnke and updates on CIZ1B research and clinical availability.

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next

Cizzle Bio Supports Early Cancer Detection at Prevent Cancer Foundation’s 2026 Gala